Literature DB >> 10996449

Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients.

J T Kuikka1, E Repo, K A Bergström, E Tupala, J Tiihonen.   

Abstract

Late onset type 1 alcoholism has been suggested to be associated with decreased dopaminergic transmission. Our hypothesis was that late onset type 1 alcoholics have also abnormal extrastriatal dopamine D(2)/D(3) receptor distribution. We performed binding, heterogeneity and laterality analysis of extrastriatal and striatal dopamine D(2)/D(3) receptors in nine late onset male alcoholics and in 12 age-matched healthy males. A radioligand, [(123)I]epidepride was used in high resolution single-photon emission tomography (SPET). Specific binding of epidepride in the left temporal pole was significantly (P<0.05) lower in type 1 alcoholics (0.74+/-0.14 ml/ml) than in controls (0.89+/-0.14 ml/ml). In alcoholics, there was no normal left-to-right asymmetry of the temporal cortical heterogeneity of epidepride distribution observed in control males (0.89+/-0.19 vs. 1.10+/-0.19; P<0.05). The results suggest that the specific binding of dopamine D(2)/D(3) receptors in late type 1 alcoholics is decreased and its laterality in the temporal brain is altered from normal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996449     DOI: 10.1016/s0304-3940(00)01423-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET.

Authors:  Masahiro Fujita; Andrea Varrone; Kyeong Min Kim; Hiroshi Watabe; Sami S Zoghbi; Nicholas Seneca; Dnyanesh Tipre; John P Seibyl; Robert B Innis; Hidehiro Iida
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

3.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

Review 4.  Imaging receptor changes in human drug abusers.

Authors:  Kelly P Cosgrove
Journal:  Curr Top Behav Neurosci       Date:  2010

Review 5.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

6.  Laterality of cortical response to ethanol is moderated by TaqIA A1 allele.

Authors:  Steven M Berman; Ernest P Noble; Parvaneh Mohammadian; Terry Ritchie; Mark A Mandelkern; Edythe D London
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

7.  Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.

Authors:  Kenneth Blum; Amanda L C Chen; Marlene Oscar-Berman; Thomas J H Chen; Joel Lubar; Nancy White; Judith Lubar; Abdalla Bowirrat; Eric Braverman; John Schoolfield; Roger L Waite; Bernard W Downs; Margaret Madigan; David E Comings; Caroline Davis; Mallory M Kerner; Jennifer Knopf; Tomas Palomo; John J Giordano; Siobhan A Morse; Frank Fornari; Debmalya Barh; John Femino; John A Bailey
Journal:  Int J Environ Res Public Health       Date:  2011-11-29       Impact factor: 3.390

Review 8.  The dopamine system and alcohol dependence.

Authors:  Hui Ma; Gang Zhu
Journal:  Shanghai Arch Psychiatry       Date:  2014-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.